The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...
Patients with stage I NSCLC who receive stereotactic body radiotherapy rarely experience acute toxicities or 90-day mortality ...
In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...
Panelists discuss how HER2-directed therapies in non–small cell lung cancer (NSCLC) are evolving, with experts examining the distinction between HER2 mutation and expression, evaluating the efficacy ...
Treatment of non-small cell lung cancer (NSCLC) depends on the stage you're in and can include chemotherapy, surgery, ...
Nuvalent achieved positive data from the phase 1/2 ALKOVE-1 study using NVL-655 for the treatment of patients with ALK-mutant ...
Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...
FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based ...
Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Pharmaceutical Technology on MSN4d
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLCThe FDA has approved AstraZeneca's Tagrisso (osimertinib) to treat adults with unresectable stage III EGFR-mutated NSCLC.
The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback